Kezar Life Sciences, Inc. Common Stock (KZR)
Kezar Life Sciences, Inc. (KZR) is a biotechnology company focused on discovering and developing novel immunomodulatory therapies for the treatment of autoimmune diseases, cancer, and inflammatory conditions. The company leverages its expertise in immune modulation and precision medicine to develop targeted treatments aimed at driving significant therapeutic benefits for patients.
Company News
Kezar Life Sciences announced a strategic review after the FDA blocked plans for a clinical trial of zetomipzomib for autoimmune hepatitis, requiring additional pharmacokinetic studies that would delay trials by approximately 2 years.
Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.
Investors should lean toward retailers as economic times get tougher, and away from autos, says Goldman Sachs.
A positive phase 2 data readout is lighting a fire underneath the biotech's shares today.